Press Release Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering Aug 28
Press Release Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ Aug 27
Press Release Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference Aug 27
Press Release Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ Aug 14
Press Release Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants Aug 12
Press Release Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants Aug 12
Press Release Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 Aug 6
Press Release Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD Jul 24